For two consecutive years, Indian has developed a new antibiotic. Last year it was Nafithromycin, breaking silence of nearly 30 years. This year, India has done it again. Zyanich, has successfully cleared all three phases of human clinical trials and received approval from Central Drug Central Organization (CDSCO), India’s central regulatory authority, for import and marketing in the country.
Developed by Wockhardt, a Mumbai based pharmaceutical and biotechnological company, Zaynich arrives at a time when superbugs, bacteria that have evolved to resist even our strongest antibiotics, are making existing medicines less effective by the day. With few new antibiotics reaching the market in recent decades, it offers a much-needed addition to a class of medicines that has seen little innovation.
But what exactly is this medicine, how does it work, and who is it for? Read till the end to find out.
Table of Contents
The Superbug Crisis and Why It’s Urgent?
Superbugs are microorganisms, bacteria, viruses, parasites or fungi that have developed resistance to the medicines meant to kill them.
More specifically, superbugs are organism that have developed multiple drug resistant, extensively Drug resistant (XDR) where almost all available antibiotics stop working or Pan drug resistant (PDR) where no known antibiotics works at all[1].
And the numbers behind this are difficult to ignore. The World Health Organization (WHO) has listed antimicrobial resistance as one of the greatest threats to global health. In India alone, AMR was linked to over 2 lakh death in 2021 [2]. Globally, drug resistant infection are projected to claim 39 million lives annually by 2050 [3], surpassing cancer as leading cause of death.
The problem is not just that superbugs exist. It’s that medicine has not kept pace. No new class of antibiotic reached the market for nearly 30 years [4], a gap that medicine is only now beginning to close. Bacteria evolved faster than science could respond. Existing antibiotics were overused, misused and pushed to their limits until many of them stopped working.
What is Zaynich and How Does it Work?
Zaynich is an injectable medicine combination of Cefepime and Zidebactam. Cefepime belongs to cephalosporin class of antibiotics while zidebactam works as both a beta-lactamase inhibitor and a non-beta-lactamase antibiotic. Together they are used to treat complicated urinary tract infections and bacterial kidney infections and are specifically designed to work against drug resistant bacteria.
The way Zaynich works inside the body is what makes it different from existing antibiotics.
Bacteria protect themselves using a cell wall. To build and maintain that wall they rely on specific proteins called Penicillin Binding Proteins, particularly PBP2 and PBP3. Zaynich blocks both of these, cutting off the bacteria’s ability to sustain its own structure.
But bacteria have another defense. They produce enzymes called beta-lactamases that are designed to break down and destroy antibiotics before they can cause any harm. Zaynich tackles this too by inhibiting those enzymes, leaving the bacteria with no shield to hide behind. [5]
By attacking on both fronts at the same time, Zaynich is able to kill bacteria that have already developed resistance to other antibiotics, which is exactly what makes it significant in the context of the superbug crisis.
It is currently approved for use in adults with complicated urinary tract infections including pyelonephritis, a serious bacterial infection of the kidneys.
And understanding why its discovery matters to India, brings us to the next part of this story.
Why is This a Milestone for India?
Zaynich follows Nafithromycin, India’s first indegenosuly developed antibiotic in three decades, which was approved in 2025 [6]. It is only the second indigenously developed antibiotic to receive approval from CDSCO. Unlike Nafithromycin, it has also received USFDA, making it the first Indian developed antibiotic in nearly 30 years to gain regulatory recognition in both India and the United States.
But the milestone goes beyond the approvals.
India is the world’s largest producer of generic medicines, but most of what it manufactures is based on discoveries made elsewhere. Zaynich changes that. It’s patented medicine, which means Wockhardt holds the exclusive right to manufacture and sell it for the duration of the patent, in India this protection last for 20 years from the filing date, with no generic version allowed until it expires. This gives the drug potential to change the narrative and establish India as a country that does not just manufacture the world’s medicine but also discovers them.
There is also a clinical reason this medicine stands apart. Most superbugs have developed immunity to antibiotics that attack from one or two angles.
Clinically, Zaynich’s three way mechanism of action gives it an edge that most existing antibiotics simply do not have against drug resistant bacteria.
What Zaynich Means for Patients?
Following are the core angles that will be addressed:
1. New Ray of Hope
For patients who have been battling urinary tract infections that simply would not respond to existing antibiotics, Zaynich offers something that was not available before. It is particularly relevant for ICU patients, people recovering from surgery, and those with weakened immunity, cases where a drug resistant infection can quickly become life threatening and where the current antibiotic arsenal often falls short.
2. Lowers the Risk of Death
Superbug infections are already claiming lives at an alarming rate and deaths linked to drug resistant bacteria are projected to increase by 70% by 2050 [3].For cUTI patients specifically, where resistance to existing antibiotics has made treatment increasingly difficult, Zaynich introduces a treatment option that could directly reduce that mortality risk.
3. Not for Everyone
This antibiotic is a reserved antibiotic, meaning it is not a medicine that will be widely prescribed or easily accessible. It is currently approved only for adults with cUTI including pyelonephritis. It is administered as an injection, not an oral tablet, which means it is a hospital setting medicine rather than something a patient picks up at a pharmacy. And until the patent period ends, it will remain expensive, putting it out of reach for most people who cannot afford private hospital care.
Conclusion
Zaynich, an Indian origin medicine, is a meaningful addition to the fight against superbugs.
For India, battling rising antibiotic resistance and growing drug resistant infections, its approval is significant. For the small group of patients it is designed for, it could be the difference between recovery and running out of options.
The bigger question now is whether this signals a turning point for pharmaceutical innovation in India, or remains an isolated breakthrough. That answer will take time. But for now, Zaynich is a step in a direction medicine has not moved in a very long time.
Mahak Phartyal completed her bachelor's in pharmacy from Veer Madho Singh Bhandari Uttarakhand Technical University. She previously worked as a Medical Writer at Meril Life Sciences, where she wrote numerous scientific abstracts for conferences such as India Live 2024 and the European Society of Cardiology (ESC). During her college years, she developed a keen research interest and published an article titled “Preliminary Phytochemical Screening, Physicochemical and Fluorescence Analysis of Nyctanthes arbor-tristis and Syzygium cumini Leaves.”
Mahak Phartyal completed her bachelor’s in pharmacy from Veer Madho Singh Bhandari Uttarakhand Technical University. She previously worked as a Medical Writer at Meril Life Sciences, where she wrote numerous scientific abstracts for conferences such as India Live 2024 and the European Society of Cardiology (ESC). During her college years, she developed a keen research interest and published an article titled “Preliminary Phytochemical Screening, Physicochemical and Fluorescence Analysis of Nyctanthes arbor-tristis and Syzygium cumini Leaves.”
